Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Enzyme may hold the key to fighting deadly parasite diseases
African tsetse fly
Enzyme could hold the key to combatting deadly parasite diseases such as African sleeping sickness, spread by the tsetse fly.

Fresh discoveries could enable the design of treatments to tackle diseases without harm to the patient

Researchers at the University of Edinburgh believe that an enzyme, found in all living things, could hold the key to combating deadly parasite diseases such as sleeping sickness.

A study into the enzyme, which helps cells convert nutrients into energy, has revealed that it is activated in various ways in different species.

The researchers say that this finding creates an opportunity to design drugs that inhibit activity of the enzyme in species that cause infection. Blocking the enzyme effectively kills the parasite, but does not affect the same enzyme in the patient.

It is hoped that the findings will lead to new treatments for diseases spread by parasites that affect millions of people in the developing world.

It is also anticipated that the discovery will ultimately help fight a variety of healthcare problems, including antibiotic resistance and some cancers.

A range of analytical techniques were employed to learn how the enzyme - pyruvate kinase - functions in bacteria, mammals and parasites.

The scientists discovered that the enzyme becomes active in all species in a similar way. A small sugar molecule binds to the enzyme to begin the process of nutrient absorption. However, each species has a unique mechanism for activating the enzyme, which provides opportunities to design drugs that block its activity in individual species.

Professor Malcolm Walkinshaw, who led the study, said: "With this discovery, we've found an Achilles heel for sleeping sickness and many other conditions. Fresh discoveries about this key enzyme - pyruvate kinase - could enable the design of treatments to tackle diseases without harm to the patient." 

Image (C) David Dennis

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.